10-KPeriod: FY2002

TERADYNE, INC Annual Report, Year Ended Dec 31, 2002

Filed March 28, 2003For Securities:TER

Summary

Teradyne, Inc.'s 2002 10-K filing reveals a company navigating a challenging economic landscape, with a significant decline in net sales and a substantial net loss compared to the previous year. The company's primary segments, Semiconductor Test Systems and Connection Systems, both experienced revenue decreases, while Circuit Board Test and Inspection Systems saw growth, largely attributed to the GenRad acquisition. Teradyne implemented significant cost-cutting measures, including workforce reductions and asset impairments, reflecting the difficult market conditions and a strategic re-evaluation of its business lines. The company's financial performance was heavily impacted by decreased customer orders, order cancellations, and pricing pressures. Despite these headwinds, Teradyne continued to invest in engineering and development, suggesting a focus on future product innovation. The balance sheet shows a decrease in total assets and a significant increase in net loss, with a substantial portion of deferred tax assets being offset by a full valuation allowance. Investors should pay close attention to the company's ability to recover demand, manage its debt obligations, and execute its product development strategy in a competitive market.

Key Highlights

  • 1Net sales decreased by approximately 15.1% to $1.22 billion in 2002 from $1.44 billion in 2001.
  • 2Teradyne reported a net loss of $718.5 million in 2002, a significant deterioration from a net loss of $202.2 million in 2001.
  • 3Semiconductor Test Systems and Connection Systems, the two largest segments, saw sales decline by 22% and 27% respectively.
  • 4Circuit Board Test and Inspection Systems sales grew by 29% year-over-year, primarily due to the full-year impact of the GenRad acquisition.
  • 5The company recorded substantial restructuring and other charges in 2002, including goodwill and intangible asset impairments totaling $86.2 million and $69.7 million in long-lived asset impairment charges.
  • 6Backlog of unfilled orders significantly decreased by 42% to $440.9 million at December 31, 2002, from $763.0 million at December 31, 2001, primarily due to customer cancellations and demand reductions.
  • 7Teradyne did not pay cash dividends, continuing its policy of reinvesting earnings for growth.

Frequently Asked Questions

Teradyne experienced a challenging year in 2002, with net sales declining by approximately 15.1% to $1.22 billion. The company reported a significant net loss of $718.5 million, a substantial increase from the $202.2 million net loss in 2001. This performance was driven by a weak global economy, reduced customer orders, and pricing pressures across its key segments, particularly Semiconductor Test Systems and Connection Systems.

The substantial net loss in 2002 was primarily due to a significant downturn in revenue, coupled with substantial restructuring and other charges. These charges included a goodwill and intangible asset impairment of $86.2 million and long-lived asset impairment charges of $69.7 million. Additionally, a full valuation allowance was established against deferred tax assets, indicating that it was more likely than not that these assets would not be realized.

The acquisition of GenRad in October 2001 positively impacted the Circuit Board Test and Inspection Systems segment, which saw a 29% increase in sales in 2002 due to the full-year impact of the acquisition. However, the acquisition also contributed to increased operating expenses and significant goodwill and intangible asset impairment charges related to this segment in 2002, highlighting the challenges in integrating and realizing the full value of the acquisition in a difficult market.

The filing indicates that while there were some signs of potential improvement in customer inventory levels and equipment utilization towards the end of 2002, the overall economic and industry conditions remained uncertain. Management noted that customers continued to defer orders, and a significant rebound in demand was not guaranteed. The company's significant investments in R&D suggest a focus on future competitiveness, but the near-term outlook remained dependent on a sustained recovery in its customers' businesses.